AstraZeneca commits an additional $100 million to venture capital arm MedImmune Ventures
Monday, 28 November 2011
MedImmune Ventures closes investment in Australian company, NeuProtect Pty Ltd
AstraZeneca today announced that it has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million. MedImmune Ventures is an evergreen venture capital fund that focuses on equity investments in private companies in the areas of biopharmaceuticals, medical and healthcare technology.